Data from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma

• DOI: 10.1158/1078-0432.c.6528354.v1
• Publication Date: 2023-04-01T01:35:25Z
• Authors: Robyn D. Gartrell; Douglas K. Marks; Emanuelle M. Rizk; Margaret Bogardus; Camille L. Gérard; Luke W. Barker; Yichun Fu; Camden L. Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S. Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J. Lee; John J. Krolewski; Carl Morrison; Basil A. Horst; Yvonne M. Saenger

<div>AbstractPurpose:<p>Biomarkers are needed to stratify patients with stage II–III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk of severe toxicity. We previously defined and validated a 53-immune gene melanoma immune profile (MIP) predictive both of distant metastatic recurrence and of disease-specific survival (DSS). Here, we test MIP on a third independent population.</p>Experimental Design:<p>A retrospective cohort of 78 patients with stage II–III primary melanoma was analyzed using the NanoString assay to measure expression of 53 target genes, and MIP score was calculated. Statistical analysis correlating MIP with DSS, overall survival, distant metastatic recurrence, and distant metastasis-free interval was performed using ROC curves, Kaplan–Meier curves, and standard univariable and multivariable Cox proportional hazards models.</p>Results:<p>MIP significantly distinguished patients with distant metastatic recurrence from those without distant metastatic recurrence using ROC curve analysis (AUC = 0.695; <i>P</i> = 0.008). We defined high- and low-risk groups based on the cutoff defined by this ROC curve and find that MIP correlates with both DSS and overall survival by ROC curve analysis (AUC = 0.719; <i>P</i> = 0.004 and AUC = 0.698; <i>P</i> = 0.004, respectively). Univariable Cox regression reveals that a high-risk MIP score correlates with DSS (<i>P</i> = 0.015; HR = 3.2).</p>Conclusions:<p>MIP identifies patients with low risk of death from melanoma and may constitute a clinical tool to stratify patients with stage II–III melanoma for enrollment in clinical trials.</p></div>